Results 71 to 80 of about 5,099,009 (221)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Skin manifestation of mantle cell lymphoma – case report and literature review [PDF]

, 2017
Mantle cell lymphoma is a rare neoplastic disease of the lymphatic system derived from mature B lymphocytes. It very commonly affects extranodal sites including the bone marrow, gastrointestinal tract and Waldeyer’s ring, but skin involvement is seen ...
Natalia Zdanowska, Agnieszka Markiewicz, Waldemar J. Placek, Mateusz M. Markiewicz, Agnieszka B. Owczarczyk-Saczonek, Dawid Sigorski   +5 more
core   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Molecular mechanisms of follicular lymphoma and its transformation [PDF]

, 2011
PhDFollicular lymphoma (FL) is the second most common form of non-Hodgkin lymphoma and at least a third of cases undergo aggressive transformation (t-FL), most frequently to diffuse large B-cell lymphoma.
Wrench, David John
core   +4 more sources

Two cases of systemic mantle cell lymphoma involving the skin

Indian Dermatology Online Journal, 2016
Mantle cell lymphoma (MCL) is a form of non-Hodgkin lymphoma that rarely affects skin. Cutaneous involvement is non-specific but usually indicates widespread disease. Herein we present two cases of MCL with secondary skin involvement.
Viktoryia Kazlouskaya, Amy Spizuoco, Jacqueline M Junkins-Hopkins   +2 more
doaj   +1 more source

Update on mantle cell lymphoma [PDF]

Blood, 2018
AbstractMantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma that is most commonly treated with combination chemo-immunotherapy at diagnosis because of the poor prognosis. More indolent presentations have been described including patients who can defer initial therapy without adverse impact on survival.
openaire   +2 more sources

Mitochondrial Morphology Dynamics Remodel Metabolism and Affect TKI Sensitivity in EGFR‐Mutated Lung Cancer

Cancer Science, EarlyView.
TKI treatment promotes mitochondrial fission and metabolic reprogramming toward oxidative phosphorylation in residual EGFR‐mutant lung cancer cells. Targeting this metabolic vulnerability restores TKI sensitivity and provides a promising strategy to overcome acquired resistance.
Yu Zhao, Yuqiang Liu, Mingxuan Xie, Zhiming Ye, Hong Huang, Maojin Yao, Feng Zhou, Jianzhu Zhao, Jun Tang   +8 more
wiley   +1 more source

Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. [PDF]

, 2011
Peripheral T-cell lymphomas (PTCL) are generally less common and pursue a more aggressive clinical course than B-cell lymphomas, with the T-cell phenotype itself being a poor prognostic factor in adult non-Hodgkin lymphoma (NHL).
Graham P. Collins, Liggins, Amanda P., Liggins, AP, Lawrie, Charles H., Banham, Alison H., Pulford, Karen, Pulford Karen, Christopher D. O. Cooper, Cooper Christopher D. O., Christian S. R. Hatton, Hatton, Christian S.R., Cooper, CD, Hatton Christian S. R., Lawrie, CH, Liggins Amanda P., Banham, Alison, Christopher D O Cooper, Hatton, CS, Banham, AH, Collins, GP, Charles H Lawrie, Pulford, K, Amanda P Liggins, Banham Alison H., Karen Pulford, Charles H. Lawrie, Amanda P. Liggins, Collins Graham P., Graham P Collins, Collins, Graham P., Alison H Banham, Christian S R Hatton, Lawrie Charles H., Cooper, Christopher D.O., Alison H. Banham   +34 more
core   +2 more sources

Aberrant Expression of Multiple T‐Cell Markers in Primary Cutaneous Follicle Center Lymphoma: A Rare Case Report

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Aberrant expression of T‐cell markers in B‐cell lymphomas is rare and can pose diagnostic challenges. We report a case of a 65‐year‐old man presenting with newly developed scalp nodules. Histopathology revealed nodular lymphoid infiltrates composed of large centrocytes and centroblasts.
V. Pfefferle, A. Vogelsberg, M. Maaß, C. M. Schürch, S. Forchhammer   +4 more
wiley   +1 more source

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

, 2010
Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success a substantial proportion of B-cell lymphomas are unresponsive or develop resistance ...
French, R.R., Johnson, P.W.M., Cox, Kerry L., Chan, Claude H.T., Johnston, David A., Glennie, Martin J., Jarrett, T.C., Glennie, M.J., Verbeek, Sjef, Chan, H.T.C., Dixon, S.V., Mora Vidal, Regina, Wijayaweera, Sahan S., Cragg, Mark S., Lim, Sean H., Dixon, Sandra V., Verbeek, J.S., French, Ruth R., Wijayaweera, S.S., Jarrett, Timothy C., Cragg, M.S., Kim, Hyung J., Kerr, Jonathan P., Vidal, R.M., Johnston, D.A., Lim, S.H., Cox, K.L., Kerr, J.P., Johnson, Peter W.M., Beers, Stephen A., Kim, H., Beers, S.A.   +31 more
core   +1 more source